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Abstract
Introduction Glutamine supplementation has beneficial effects
on morbidity and mortality in critically ill patients, possibly in part
through an attenuation of the proinflammatory cytokine
response and a stimulation of heat shock protein (HSP)70. We
infused either alanine-glutamine or saline during endotoxin
challenge and measured plasma cytokines and HSP70 protein
expression.
Methods This crossover study, conducted in eight healthy
young men, was double-blind, randomized and placebo-
controlled. It was performed on 2 trial days, separated by a 4-
week washout period. The volunteers received an infusion of
alanine-glutamine at a rate of 0.025 g/(kg body weight × hour)
or saline for 10 hours. After 2 hours, an intravenous bolus of
Escherichia coli endotoxin (0.3 ng/kg) was administered. Blood
samples were collected hourly for the following 8 hours. HSP70
protein content in isolated blood mononuclear cells (BMNCs)
was measured by Western blotting.
Results Plasma glutamine increased during alanine-glutamine
infusion. Endotoxin reduced plasma glutamine during both trials,
but plasma glutamine levels remained above baseline with
alanine-glutamine supplementation. Endotoxin injection was
associated with alterations in white blood cell and differential
counts, tumour necrosis factor-α, IL-6, temperature and heart
rate, but glutamine affected neither the endotoxin-induced
change in these variables nor the expression of HSP70 in
BMNCs.
Conclusions Endotoxin reduced plasma glutamine
independently of alanine-glutamine infusion, but
supplementation allows plasma levels to be maintained above
baseline. Glutamine alters neither endotoxin-induced systemic
inflammation nor early expression of HSP70 in BMNCs.
Trial Registration ClinicalTrials.gov ID: NCT 00780520.
Introduction
The level of glutamine in plasma as well as in skeletal muscle
is depressed in critically ill patients compared with healthy
control individuals [1], and low glutamine levels in plasma and
muscles are associated with poor outcome [2,3]. In light of
these findings, glutamine has been classified as a 'condition-
ally essential amino acid', in that it is usually a nonessential
amino acid that must be supplemented during situations such
as critical illness [4], when endogenous glutamine production,
mainly in skeletal muscle, cannot keep up with the increased
demand. Several clinical trials of parental as well as enteral
glutamine supplementation to critically ill patients have shown
a beneficial effect both on infectious complications [5-7] and
mortality [8,9]; however, others were unable to detect
improvements in mortality or morbidity with parental supple-
mentation [10]. A meta-analysis of studies involving enterally
as well as parentally administered glutamine to seriously ill
patients identified a nonsignificant trend toward a positive
effect of high-dose parental glutamine on mortality and infec-
tious complications [11]. Because of heterogeneity in patient
populations included and the insufficient power of many of the
conducted trials, the clinical relevance of glutamine supple-
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mentation is still debated. On reviewing the literature, how-
ever, it appears that the beneficial effects of glutamine may
increase with higher doses or parenteral administration [12].
The association between low levels of glutamine, increased
mortality and morbidity, and the potential beneficial effect of
parental supplementation is still not fully understood. Animal
studies have revealed that glutamine supplementation attenu-
ates the release of the proinflammatory cytokines tumour
necrosis factor (TNF)-α and IL-6 in septic animals and
improves survival [13,14]; hence, a positive effect of parental
glutamine administration to critically ill patients may – at least
in part – be due to a modulation of excessive proinflammatory
cytokine release during the systemic inflammation associated
with critical illness in general, and with severe sepsis in partic-
ular.
Glutamine induces expression of the anti-inflammatory heat
shock protein (HSP)70 in cell cultures [15], animals [16-19]
and critically ill patients [20]. Rodents subjected to stimuli that
are known to induce a high intracellular level of HSPs and sub-
sequent induction of otherwise lethal sepsis exhibited attenu-
ated release of TNF-α and IL-6 and reduced mortality [21-23].
Based on these findings, the positive effect of glutamine in crit-
ical illness may be due either to a direct anti-inflammatory
effect of glutamine or to a glutamine-dependent increased
expression of HSP70 and the anti-inflammatory effects of this
protein.
In the present study we hypothesized that intravenous admin-
istration of glutamine attenuates the immune response during
acute inflammation. We thus established a human in vivo sep-
sis model (the human endotoxin model) in order to investigate
the effect of glutamine on the response of TNF-α, IL-6, cortisol
and white blood cell (WBC) subpopulations to a standardized
inflammatory stimulus (intravenous injection of E. coli endo-
toxin). Furthermore, we set out to determine the early effects
of glutamine and endotoxin on HSP70 content in immune
cells, in order to test the hypothesis that the HSP70 content
would increase during glutamine infusion but not be further
affected by endotoxin.
Materials and methods
Volunteers
Eight healthy young men (mean age 27.3 years, range 21 to
33 years) with body mass index 23.9 kg/m2 (range 20.7 to
28.4 kg/m2), an unremarkable medical history and no regular
medication use were included in the study after they had given
informed oral and written consent. All participants underwent
a thorough clinical examination, including blood analyses (hae-
moglobin, WBC and differential counts, C-reactive protein,
blood glucose, electrolytes, and liver, kidney and thyroid func-
tion parameters) and electrocardiogram recording. All tests
were normal. The Ethical Committee of the Capital Region,
Denmark, approved the study ([H-KF] 01-144/98).
Materials
Glutamine was given as a dipeptide, consisting of alanine-
glutamine (Dipeptiven; Fresenius Kabi, Uppsala, Sweden) in a
stock concentration of 200 mg/ml of the dipeptide suspended
in saline. The solution used for infusion was a 20% (volume/
volume) solution of Dipeptiven and saline. Isotonic saline was
used as a placebo. The dipeptide solution could not visually be
distinguished from placebo, and the containers were covered
in a way that prevented both the volunteers and the investiga-
tors from distinguishing between them. The glutamine solution
and saline were prepared under sterile conditions on the day
before each trial.
Study design
The study was a randomized, double-blinded, placebo-control-
led, crossover trial. All volunteers participated on 2 trial days,
separated by 30 days. The volunteers were randomly assigned
to either infusion with alanine-glutamine on the first trial day
and placebo on the second (n = 5) or vice versa (n = 3). The
difference in the numbers of volunteers was due to one being
placed in the wrong group (human error).
The volunteers reported to the research unit at 06:30 a.m.
after an overnight fast. They were immediately placed in bed.
Catheters were placed bilaterally into an antecubital vein; one
catheter was used to draw blood samples and the other to
infuse glutamine or placebo. The volunteers were monitored
by continuous electrocardiography, noninvasive blood pres-
sure monitoring (every 15 minutes) and continuous measure-
ment of rectal temperature and venous oxygen saturation. At
07:00 a.m. (t = 0), infusion with glutamine or placebo was ini-
tiated and continued for 10 hours. The glutamine infusion rate
was set at 0.025 g/(kg body weight × hour). This rate has
been tested for safety [24] and is comparable to the doses
used in patient studies [5,6,8]. Placebo was infused at the
same rate. At 09:00 a.m., after 2 hours of alanine-glutamine or
placebo infusion, steady state was assumed to have been
achieved [24] and volunteers were given an intravenous bolus
injection with a standard reference E. coli endotoxin (Lot EC-
6; US Pharmacopeia Convention, Rockville, MD, USA) at a
dose of 0.3 ng/kg body weight. The vounteers were then mon-
itored for another 8 hours.
Blood sample and analysis of blood samples
Blood samples were drawn hourly from 0 hours and onward,
with additional samples at time 2.5 and 3.5 hrs (corresponding
to 0.5 and 1.5 hours, respectively, after endotoxin injection).
Whole blood was analyzed for WBC and differential counts
using standard biochemical procedures.
Samples for measuring plasma concentrations of glutamine,
cytokines and cortisol were drawn into tubes containing EDTA
and centrifuged; plasma was separated and immediately
stored at -80°C. Plasma glutamine concentration was deter-
mined enzymatically using an automated analyzer (CobasAvailable online http://ccforum.com/content/13/1/R7
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Fara; F. Hoffmann-La Roche, Basel, Switzerland). Plasma
TNF-α, IL-6 and cortisol levels were determined using a com-
mercially available enzyme-linked immunosorbent assay
(Quantikine and Parameter; R&D systems, Minneapolis, MN,
USA). All measurements were taken in duplicate and means
were calculated for the subsequent statistical analyses. Blood
for isolation of blood mononuclear cells (BMNC) was drawn
into tubes containing heparin; BMNCs were isolated by den-
sity gradient centrifugation (Lymphoprep Nycomed Pharma
AS, Oslo, Norway) on LeucoSep tubes (Greiner, Fricken-
hausen, Germany). After separation, the BMNCs were imme-
diately suspended in a modified RIPA cell lysis buffer (50
mmol/l Tris-HCl [pH 7.4], 150 mmol/l NaCl, 1 mmol/l EGTA, 1
mmol/l EDTA, 0.25% NaDeoxycholate, 1% Triton X-100) con-
taining complete protease inhibitor cocktail (Roche, Basel,
Switzerland) and frozen at -80°C until measurement of HSP70
protein content using Western blotting, as described below.
HSP70 Western blotting
BMNCs resuspended in cell lysis buffer were thawed on ice,
pulled through a small-gauge syringe four to five times, and
centrifuged in a microcentrifuge at maximum speed at 4°C for
15 minutes. The supernatant was then transferred to a new
Eppendorf tube, and protein concentrations in this BMNC
lysate were determined using the BioRad DC kit (BioRad, Her-
cules, CA, USA) with bovine serum albumin as standard. All
measurements were conducted in triplicate.
Ten micrograms of BMNC protein lysate per lane were boiled
in Laemmli buffer and separated on 4% to 12% Bis-Tris gels
(Invitrogen, Taastrup, Denmark) and transferred to polyvinyli-
dene fluoride membranes (Hybond-P; GE Healthcare, Little
Chalfont, UK). Membranes were blocked for 1 hour at room
temperature in a blocking buffer (Tris-buffered saline [pH 7.6],
0.1% Tween-20, 5% skimmed milk). The membranes were
then incubated overnight at 4°C in a blocking buffer containing
a primary antibody against HSP70 (SPA-810; Stressgen, Vic-
toria, BC, Canada) at a 1:1,000 dilution. Subsequently, they
were washed three times for 5 minutes in a washing buffer
(Tris-buffered saline with 0.1% Tween-20) and incubated for
1 hour at room temperature with a secondary antibody (Rabbit
anti-mouse HRP, P0260; Dako, Glostrup, Denmark) at a
1:10,000 dilution in a blocking buffer, followed by three
washes of 5 minutes each in washing buffer. The protein
bands were detected using ECL (GE Healthcare) and quanti-
fied using CCD image sensor (ChemiDoc XRS; BioRad) and
software (Quantity One; BioRad).
Statistical analyses
All statistical analyses were done using SAS 9.1 (SAS Insti-
tute Inc., Cary, NC, USA). Log values were used when consid-
ered appropriate to approximate the normal distribution. P <
0.05 was considered statistically significant. A two-way analy-
sis of variance for longitudinal measures was performed on
each investigated variable using a means model (SAS PROC
MIXED) with the model TIME TREATMENT TIME*TREAT-
MENT, and with SUBJECT as a random factor. An autoregres-
sive covariate structure was assumed. Goodness-of-fit of the
mixed model was assessed by investigating the distribution of
the residuals. Significant changes in inflammatory markers
from the time of endotoxin administration to the following time
points were analyzed by paired t-tests using the Tukey-Kramer
method to adjust for multiple comparisons. Fractional changes
in glutamine levels from baseline to endotoxin injection and
from endotoxin injection to 4 hours after endotoxin injection
were calculated and evaluated by t-tests.
Results
Plasma glutamine
Plasma glutamine concentration increased by 55% (95% con-
fidence interval [CI] = 42% to 68%; P < 0.0001) above base-
line levels (from 500 μmol/l [95% CI = 430 to 570 μmol/l] to
764 μmol/l [95% CI = 708 to 821 μmol/l]) during the first 2
hours of glutamine infusion; in contrast, plasma glutamine did
not change during placebo infusion (Figure 1a). Two hours
after endotoxin administration, plasma glutamine decreased
with both treatments, reaching a nadir after 4 hours and then
gradually normalizing. When glutamine was infused, plasma
levels dropped by 21% (95% CI = 16% to 27%; P < 0.0001),
from 764 μmol/l (95% CI = 708 to 821 μmol/l) at the time of
endotoxin injection to 601 μmol/l (95% CI = 523 to 679 μmol/
l) 4 hours later; plasma levels thus remained above baseline
levels throughout the trial. During placebo infusion, plasma lev-
els also dropped significantly, from 484 μmol/l (95% CI = 427
to 541 μmol/l) to 369 μmol/l (95% CI = 333 to 406 μmol/l),
corresponding to a fractional decrease of 23% (95% CI =
15% to 31%; P = 0.0003). The endotoxin-induced drop in
plasma glutamine – absolute as well as fractional – was com-
parable between treatments.
Cytokines
TNF-α (P < 0.0001) and IL-6 (P < 0.05) plasma concentra-
tions both increased after endotoxin administration. However,
infusion with glutamine had no effect on the response of either
cytokine to endotoxin injection (Figure 1b,c).
Heat shock protein-70
BMNCs were isolated at baseline and after 2 and 4 hours. No
significant changes were detected in BMNC HSP70 protein
concentrations over time or between trials (Figure 2).
Other variables
Endotoxin injection induced characteristic changes (P < 0.05)
in the concentration of monocytes, lymphocytes and neu-
trophils, but these changes were unaffected by the infusion of
glutamine (Figure 3a–c). The plasma concentration of cortisol
decreased significantly during the first 2 hours of both
glutamine and placebo infusions (P < 0.0001). After endotoxin
administration, plasma cortisol increased (P < 0.0001), but
the time course was unaffected by glutamine (Figure 1d).Critical Care    Vol 13 No 1    Andreasen et al.
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Figure 1
Evolution of clinical and biochemical variables after endotoxin challenge and infusion with glutamine or placebo Evolution of clinical and biochemical variables after endotoxin challenge and infusion with glutamine or placebo. Shown is the time course of clinical 
and biochemical variables after an intravenous bolus of endotoxin (vertical dotted line indicates time of endotoxin administration) and infusion with 
glutamine (squares) or placebo (triangles) in young healthy volunteers: (a) plasma glutamine, (b) IL-6, (c) tumour necrosis factor (TNF)-α, (d) corti-
sol, (e) rectal temperature and (f) heart rate. Values are expressed as means ± standard error of the mean. The result of a mixed model analysis is 
given below each graph. In panels e and f, hourly measurements are shown for clarity, although measurements performed every 15 minutes were 
included in the analysis. *P < 0.05, post hoc t-test from the start of the trial to the time of endotoxin administration; #P < 0.05, post hoc t-test of the 
difference from administration of endotoxin to time point during placebo infusion.Available online http://ccforum.com/content/13/1/R7
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Heart rate and temperature both increased (P < 0.05) after
endotoxin administration but were unaltered by glutamine infu-
sion (Figure 1e,f).
Discussion
This in vivo human study demonstrates a marked decrease in
plasma glutamine levels caused by intravenous injection of
endotoxin, the decrease being independent of the administra-
tion of glutamine. However, glutamine supplementation
allowed volunteers to maintain plasma levels above baseline in
spite of the endotoxin-induced drop. In contrast, plasma levels
dropped below baseline when placebo was infused. This find-
ing could be of clinical relevance, because patients with sep-
sis may experience several infectious bouts during their illness,
potentially depleting plasma glutamine levels successively, if
supplementation is not given. Clinical trials have shown that
both the plasma glutamine concentration and the muscle intra-
cellular glutamine content decline during severe sepsis and
critical illness [1,2], and the magnitude of decline in plasma
glutamine has been associated with increased mortality [3].
The potential mechanisms that underlie the decrease in
plasma glutamine during critical illness are yet to be unrav-
elled. The liver exhibits increased uptake of glutamine during
endotoxaemia in rats [25], possibly for the synthesis of acute
phase reactants; in addition, immune cells may utilize
glutamine at a higher rate during critical illness [26,27]. These
mechanisms may also account for the drop observed in our
study. Furthermore, the onset of the decline in plasma
glutamine in our study coincided with the peak concentrations
of plasma TNF-α and IL-6 at respectively 2 and 3 hours after
endotoxin administration. Our research group previously
showed that infusion of recombinant human IL-6 at high doses
to healthy volunteers lowers plasma glutamine substantially
[28]. These findings suggest that IL-6 may play a role in the
reduction in glutamine levels during inflammation.
The aim of the present study was to investigate whether
glutamine infusion had an effect on the cytokine and WBC
response to endotoxin. Refuting our hypothesis, we were una-
ble to detect any effect of glutamine on either cytokines or the
HSP70 content in BMNCs. Data from animal and cell line
studies have shown that glutamine may have anti-inflammatory
properties, and that this could be linked to increased intracel-
lular concentrations of HSP70 protein. Inflammation is
regarded to be a major contributor to the pathological conse-
quences of sepsis, and it has been suggested that treatments
able to attenuate the inflammatory response may improve sur-
vival [29,30]. We infused glutamine at clinically relevant rates
that have been tested for safety [24]. We achieved an increase
Figure 2
Evolution of HSP70 concentrations after endotoxin challenge and infusion with glutamine or placebo Evolution of HSP70 concentrations after endotoxin challenge and infusion with glutamine or placebo. Shown is the time course of heat shock pro-
tein (HSP)70 concentrations in blood mononuclear cells after endotoxin administration (vertical dotted line indicates time of injection) and infusion 
with glutamine (squares) or placebo (triangles). Values are expressed as mean ± standard error of the mean. The result of a mixed model analysis is 
given below the figure.Critical Care    Vol 13 No 1    Andreasen et al.
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in plasma glutamine of 55% above baseline, but we cannot
exclude the possibility that our inability to detect significant
attenuation of cytokine levels or induction of HSP70 protein
synthesis resulted from an insufficient dose or inadequate
duration of administration. Previous studies of HSP70 in
humans have identified substantial variation because of a vari-
ety of factors (for example, body temperature [31]), and the
endotoxin-mediated increases in cytokines are known to
exhibit large interindividual variations. Thus, the lack of positive
findings in the present study may also be ascribed to a small
number of volunteers, and the present findings should be inter-
preted with caution.
Conclusion
According to the results of the present study, endotoxin
decreased plasma glutamine levels. However, parenteral sup-
plementation of glutamine allowed the volunteers to maintain
their plasma glutamine above baseline levels, even though the
metabolism of glutamine in itself was unaffected by glutamine
supplementation, as demonstrated by a marked and compara-
ble decline in plasma glutamine after endotoxin injection in the
two groups. In contrast to our hypothesis, glutamine adminis-
tration had no effect on the cytokine or WBC response to
endotoxin and did not change the expression of HSP70 pro-
tein in BMNCs.
Figure 3
Evolution of leucocyte subpopulations after endotoxin challenge and infusion with glutamine or placebo Evolution of leucocyte subpopulations after endotoxin challenge and infusion with glutamine or placebo. Shown is the time course of leucocyte sub-
populations in plasma after endotoxin administration (vertical dotted line indicates time of injection) and infusion with glutamine (squares) or placebo 
(triangles): (a) monocytes, (b) lymphocytes and (c) neutrophils. Values are expressed as mean ± standard error of the mean. The result of a mixed 
model analysis is given below each graph. #P < 0.05, post hoc t-test of difference from administration of endotoxin to time point during placebo infu-
sion.Available online http://ccforum.com/content/13/1/R7
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